India, Sept. 29 -- Tuesday, Ernexa Therapeutics (ERNA) said it has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, where CEO Sanjeev Luther will present the company's oncology strategy and lead candidate ERNA-101.
Luther is scheduled to deliver an Innovation Spotlight presentation on October 6, highlighting Ernexa's focused oncology strategy, beginning with the development of ERNA-101 in platinum-resistant ovarian cancer and its potential expansion into other ovarian cancer and solid tumor indications.
ERNA-101 is an investigational cell therapy designed to activate and regulate the immune response to recognize and attack cancer cells.
The therapy is being developed using Ernexa's synthetic induced mesen...